Rapid Micro Biosystems (RPID) Common Equity (2020 - 2026)

Rapid Micro Biosystems (RPID) has 7 years of Common Equity data on file, last reported at $20.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 68.85% year-over-year to $20.4 million; the trailing twelve-month figure through Mar 2026 stood at $20.4 million (down 68.85% YoY), and the FY2025 full-year result was $33.2 million, down 55.93% from the prior year.
• Common Equity retreated to $20.4 million in Q1 2026, from $33.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $207.1 million in Q1 2022 to a low of $20.4 million in Q1 2026.
• A 5-year average of $109.5 million and a median of $105.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 237.09% in 2022 and slumped 68.85% in 2026, its largest moves.
• Tracing RPID's Common Equity over 5 years: stood at $164.2 million in 2022, then slipped by 28.13% to $118.0 million in 2023, then sank by 36.14% to $75.4 million in 2024, then slumped by 55.93% to $33.2 million in 2025, then tumbled by 38.57% to $20.4 million in 2026.
• Business Quant data shows RPID's Common Equity at $20.4 million in Q1 2026, $33.2 million in Q4 2025, and $44.3 million in Q3 2025.